{
  "meta": {
    "title": "54_Targeted_Therapy_And_Monoclonal_Antibodies",
    "url": "https://brainandscalpel.vercel.app/54-targeted-therapy-and-monoclonal-antibodies-25a0997e.html",
    "scrapedAt": "2025-11-30T18:17:03.253Z"
  },
  "questions": [
    {
      "text": "A 45 y/o male presents with fatigue, unintentional weight loss, and left upper quadrant abdominal discomfort. Physical examination shows splenomegaly. Lab tests show leukocytosis. The peripheral blood smear shows increased basophils, myelocytes, and segmented neutrophils. Bone marrow biopsy confirms hypercellularity with increased myeloid precursors and the presence of the Philadelphia chromosome (BCR-ABL fusion gene). Which of the following drugs would be your DOC to treat the patient?",
      "choices": [
        {
          "id": 0,
          "text": "Ponatinib"
        },
        {
          "id": 1,
          "text": "Imatinib"
        },
        {
          "id": 2,
          "text": "Nilotinib"
        },
        {
          "id": 3,
          "text": "Dasatinib"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) </strong><strong>Imatinib</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The clinical scenario given, describes a patient who has CML.</p>\n\n<p>Chronic <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">Myeloid</span> <span class=\"customMeta\" data-dictid=\"4521dbf4b91692777191a73002bf98\">Leukemia</span> (CML) is a <span class=\"customMeta\" data-dictid=\"8dd789d7d1169277719303d4744837\">myeloproliferative</span> disorder characterized by the presence of the Philadelphia chromosome, resulting from a <span class=\"customMeta\" data-dictid=\"5afb1c86751692777197cf9452d41b\">reciprocal</span> <span class=\"customMeta\" data-dictid=\"8ba7332e86169277720060bd4507c8\">translocation</span> between chromosomes 9 and 22 [t(9;22)(q34;q11)], which generates the BCR-ABL <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> gene. This <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> gene encodes a constitutively active tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> that drives the uncontrolled <span class=\"customMeta\" data-dictid=\"8eedb6cec61692777196a6a3b93d3f\">proliferation</span> of <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">myeloid</span> cells</p>\n\n<p>Imatinib binds to the ABL <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> portion of the BCR-ABL tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> receptor, inhibiting its <span class=\"customMeta\" data-dictid=\"ccd357daaf16927771825777ea6a0d\">attachment</span> and preventing cell division. By inhibiting this <span class=\"customMeta\" data-dictid=\"c98928d9d516927771805d7cdd0d06\">aberrant</span> tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> activity, Imatinib selectively targets the underlying cause of CML, leading to <span class=\"customMeta\" data-dictid=\"f03ca2d2a716927771901227bc175a\">inhibition</span> of leukemic cell <span class=\"customMeta\" data-dictid=\"8eedb6cec61692777196a6a3b93d3f\">proliferation</span> and <span class=\"customMeta\" data-dictid=\"f447020b9616927771904d1c923d80\">induction</span> of apoptosis.</p>\n\n<p><strong>Ponatinib (Option A), Nilotinib (Option </strong><strong>C) & </strong><strong>Dasatinib (Option </strong><strong>D)</strong><strong>, </strong>and Bosutinib can also be used for treating <span class=\"customMeta\" data-dictid=\"32c39405871692777184d06d6c01ab\">CML</span> but neither of them is <span class=\"customMeta\" data-dictid=\"357ecf18f2169277718661a76111ea\">DOC</span> for CML.</p>\n\n<ul>\n\t<li>Dasatinib and Nilotinib are used in Imatinib-resistant cases.</li>\n\t<li>Ponatinib is used in <span class=\"customMeta\" data-dictid=\"40a432892e1692777185b0cf235a9d\">Dasatinib</span> and Nilotinib-resistant cases. In further resistant cases, Omacetaxine.</li>\n</ul>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:498px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Generation</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drugs</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>1st Generation</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Erlotinib</li>\n\t\t\t\t<li>Gefitinib</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>2nd Generation</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Afatinib</li>\n\t\t\t\t<li>Dacomitinib</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3rd Generation</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Osimertinib</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>4th Generation</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Mobocertinib</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/o7UHOyOq5d0gJ6lmMBuX1749201478.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/2fa4ph8knsNFYrP4xDMm1749201407.mp3"
    },
    {
      "text": "A 60-year-old female patient diagnosed with a gastrointestinal stromal tumor (GIST) has been started on first-line treatment. Genetic testing reveals a mutation in the c-KIT gene. After several months, the patient develops resistance to the initial therapy. The oncologist considers alternative medications. Which of the following drugs is specifically known for selectively inhibiting the Platelet-Derived Growth Factor Receptor (PDGFR) rather than multiple tyrosine kinase receptors?",
      "choices": [
        {
          "id": 0,
          "text": "Imatinib"
        },
        {
          "id": 1,
          "text": "Sunitinib"
        },
        {
          "id": 2,
          "text": "Ripretinib"
        },
        {
          "id": 3,
          "text": "Regorafenib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Ripretinib</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li><strong>Ripretinib</strong> is a <strong>switch-control tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitor</strong> developed for use in <strong>GIST</strong>, particularly after resistance to other TKIs.<br />\n\t </li>\n\t<li>It selectively targets <span class=\"customMeta\" data-dictid=\"5663b887111692777193059c055492\">mutant</span> forms of <strong>KIT and PDGFRα</strong>, offering improved <span class=\"customMeta\" data-dictid=\"f03ca2d2a716927771901227bc175a\">inhibition</span> of a wide spectrum of mutations, but with more <strong>specificity for PDGFR</strong> compared to multikinase inhibitors like sunitinib and regorafenib.<br />\n\t </li>\n\t<li>It is used as <strong>fourth-line treatment</strong> in GIST after failure of imatinib, sunitinib, and regorafenib.<br />\n\t </li>\n</ul>\n\n<p><strong>GIST treatment and <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> targets comparison:</strong><br />\n </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Primary Targets</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Line of Therapy in GIST</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Imatinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>c-KIT, PDGFRα</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>First-line</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Sunitinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Multiple TKs: KIT, PDGFR, VEGFR</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Second-line</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Regorafenib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Multikinase: KIT, PDGFR, VEGFR, RAF, etc.</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Third-line</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Ripretinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Broad-spectrum KIT and PDGFRα <span class=\"customMeta\" data-dictid=\"f03ca2d2a716927771901227bc175a\">inhibition</span> (switch-control)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Fourth-line or resistant cases</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><br />\n </p>\n\n<p><strong>Imatinib (Option A):</strong> Incorrect - though it targets PDGFR, it is not selective and also targets BCR-ABL, KIT, etc.<br />\n </p>\n\n<p><strong>Sunitinib (Option B):</strong> Incorrect - a <strong>broad multikinase inhibitor</strong>, including PDGFR, VEGFR, KIT, FLT3.<br />\n </p>\n\n<p><strong>Regorafenib (Option D):</strong> Incorrect - a <strong>broad-spectrum multikinase inhibitor</strong> with less <span class=\"customMeta\" data-dictid=\"e70dd3ea9916927771988faba61d64\">specificity</span> for PDGFR.</p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/PjyAPnu9vpOR3j6ASqrB1748866483.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/irzp92LhXbYM7b17NLJi1748863838.mp3"
    },
    {
      "text": "Which of the following conditions is not commonly treated with Bruton’s Tyrosine Kinase (BTK) inhibitors?",
      "choices": [
        {
          "id": 0,
          "text": "Mantle Cell Lymphoma"
        },
        {
          "id": 1,
          "text": "Marginal Zone Lymphoma"
        },
        {
          "id": 2,
          "text": "Chronic Lymphocytic Leukemia"
        },
        {
          "id": 3,
          "text": "Hodgkin's Lymphoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) Hodgkin's Lymphoma</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li><strong>Bruton’s Tyrosine Kinase (BTK) inhibitors</strong> such as <strong>Ibrutinib</strong>, <strong>Acalabrutinib</strong>, and <strong>Zanubrutinib</strong> are highly effective in <strong>B-cell malignancies</strong> where BCR <span class=\"customMeta\" data-dictid=\"f9016f36fd1692777198b0fd5e9c6d\">signaling</span> plays a central role.<br />\n\t </li>\n\t<li><strong>Hodgkin's lymphoma</strong>, however, is <strong>not a B-cell receptor–driven malignancy</strong> and thus <strong>not commonly treated</strong> with BTK inhibitors.<br />\n\t </li>\n\t<li>Standard treatment for Hodgkin’s <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">lymphoma</span> includes <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> (e.g., ABVD regimen) and <span class=\"customMeta\" data-dictid=\"2c003a40ea1692777189ec17568ab1\">immunotherapy</span> (e.g., anti-CD30 antibodies like Brentuximab vedotin), <strong>not BTK inhibitors</strong>.<br />\n\t </li>\n</ul>\n\n<p><strong>BTK <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">Inhibitor</span> Use in Hematologic Malignancies</strong><br />\n </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Condition</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>BTK <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">Inhibitor</span> Use</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Comments</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Mantle Cell Lymphoma</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Yes</strong> (e.g., Ibrutinib)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Approved indication</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Marginal Zone Lymphoma</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Yes</strong> (e.g., Zanubrutinib)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Used especially in relapsed/refractory settings</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Chronic Lymphocytic Leukemia</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Yes</strong> (Ibrutinib, Acalabrutinib)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>First-line and relapsed settings</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Hodgkin's Lymphoma</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>No</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Not a BTK-driven disease; treated with chemotherapy/immunotherapy</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><br />\n </p>\n\n<p><strong>Mantle Cell <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">Lymphoma</span> (Option A):</strong> Incorrect. BTK inhibitors are approved and effective.<br />\n </p>\n\n<p><strong>Marginal Zone <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">Lymphoma</span> (Option B):</strong> Incorrect. BTK inhibitors like Zanubrutinib are used here.<br />\n </p>\n\n<p><strong>Chronic Lymphocytic Leukemia (Option C):</strong> Incorrect. BTK inhibitors are a cornerstone of therapy.<br />\n </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/TCaOm650CFzyYCnMibPq1749201583.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/Z6T5BKrvKuOOYh2tgw111749201532.mp3"
    },
    {
      "text": "Match the following drugs to their appropriate mutation targets in cancer treatment:\n\n\n\t\n\t\t\n\t\t\t\n\t\t\t1. Erlotinib\n\t\t\t\n\t\t\tA. HER2 (+)ve Breast Cancer\n\t\t\t \n\t\t\n\t\t\n\t\t\t\n\t\t\t2. Osimertinib\n\t\t\t\n\t\t\tB. HER1 (EGFR) mutation in Non-Small Cell Lung Cancer\n\t\t\t \n\t\t\n\t\t\n\t\t\t\n\t\t\t3. Lapatinib\n\t\t\t\n\t\t\tC. T790M mutation in EGFR receptor\n\t\t\t \n\t\t\n\t\t\n\t\t\t4. Neratinib\n\t\t\tD. Trastuzumab resistant HER2 (+)ve Breast Cancer",
      "choices": [
        {
          "id": 0,
          "text": "1-C, 2-B, 3-D, 4-A"
        },
        {
          "id": 1,
          "text": "1-B, 2-C, 3-A, 4-D"
        },
        {
          "id": 2,
          "text": "1-C, 2-B, 3-A, 4-D"
        },
        {
          "id": 3,
          "text": "1-B, 2-C, 3-D, 4-A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer</strong>: <strong>D) 1-B, 2-C, 3-D, 4-A</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Matched Target</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Mechanism & Clinical Use</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Erlotinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>B. HER1 (EGFR) <span class=\"customMeta\" data-dictid=\"7a67bdf6f81692777193cfd480f228\">mutation</span> in NSCLC</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Reversible tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> (TKI) of <strong>EGFR (HER1)</strong>; used in <strong>EGFR-mutant NSCLC</strong>.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Osimertinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>C. T790M EGFR mutation</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>3rd-generation <span class=\"customMeta\" data-dictid=\"ee77d507701692777190bfcf47b497\">irreversible</span> EGFR-TKI that targets <strong>T790M</strong>, a common resistance mutation.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Lapatinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>A. HER2 (+)ve Breast Cancer</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Dual <strong>HER2 and EGFR</strong> TKI used for <strong>HER2-positive breast cancer</strong>, usually after trastuzumab.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Neratinib</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>D. Trastuzumab-resistant HER2+ Cancer</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Irreversible pan-HER <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> <span class=\"customMeta\" data-dictid=\"e4865847fa169277720044d7b530b0\">targeting</span> <strong>HER1, HER2, and HER4</strong>, effective after <span class=\"customMeta\" data-dictid=\"3c1f84a831169277720091463322a7\">trastuzumab</span> failure.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<h3><strong>Targeted Therapy in Oncology</strong></h3>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Target</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Common Mutation/Context</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Targeted Drugs</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>EGFR (HER1)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>NSCLC with EGFR mutations</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Erlotinib, Gefitinib, Afatinib</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>T790M mutation</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Resistance <span class=\"customMeta\" data-dictid=\"7a67bdf6f81692777193cfd480f228\">mutation</span> in EGFR+ NSCLC</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Osimertinib</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>HER2</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>HER2-positive breast cancer</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Trastuzumab, Pertuzumab, Lapatinib, Neratinib</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Trastuzumab-resistance</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>HER2+ breast cancer non-responsive to trastuzumab</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Neratinib, Tucatinib</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/luCUITBGFj6QRRmxOs2S1746256860.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/UHh4nbz2Agxzg2FYJZKa1746256783.mp3"
    },
    {
      "text": "Match the drugs & their clinical use:\n\n\n\t\n\t\t\n\t\t\t\n\t\t\tDrug \n\t\t\t\n\t\t\t\n\t\t\tClinical Use\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t1. Pazopanib\n\t\t\t\n\t\t\t\n\t\t\tA. Cholangiocarcinoma\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t2. Midostaurin\n\t\t\t\n\t\t\t\n\t\t\tB. Urothelial Carcinoma\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t3. Erdafitinib\n\t\t\t\n\t\t\t\n\t\t\tC. Acute Myeloid Leukemia (AML) with FLT-3 mutation\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t4. Infigratinib\n\t\t\t\n\t\t\t\n\t\t\tD. Renal Cell Carcinoma (RCC)",
      "choices": [
        {
          "id": 0,
          "text": "1-D, 2-C, 3-B, 4-A"
        },
        {
          "id": 1,
          "text": "1-D, 2-C, 3-A, 4-B"
        },
        {
          "id": 2,
          "text": "1-C, 2-D, 3-A, 4-B"
        },
        {
          "id": 3,
          "text": "1-C, 2-D, 3-B, 4-A"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct Answer: A) 1-D, 2-C, 3-B, 4-A</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li><strong>Pazopanib -</strong> VEGFR Inhibitor- <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">Renal</span> Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC)</li>\n\t<li><strong>Midostaurin - </strong>VEGFR Inhibitor- <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">Acute</span> <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">Myeloid</span> <span class=\"customMeta\" data-dictid=\"4521dbf4b91692777191a73002bf98\">Leukemia</span> (AML) with FLT-3 mutation</li>\n\t<li><strong>Erdafitinib </strong>- FGFR Inhibitor- Urothelial Carcinoma</li>\n\t<li><strong>Infigratinib -</strong> FGFR Inhibitor- Cholangiocarcinoma</li>\n</ul>\n\n<p><strong>VEGFR Inhibitors and uses:</strong></p>\n\n<table cellspacing=\"0\" style=\"width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p><strong>Drug Name</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p><strong>Clinical Use</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Pazopanib, Axitinib, Tivozanib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC)</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Sorafenib, Lenvatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC), <span class=\"customMeta\" data-dictid=\"6165f47a8c1692777188c0dfc0d75d\">Hepatocellular</span> <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (HCC)</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Sunitinib, Regorafenib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC), <span class=\"customMeta\" data-dictid=\"b3a647ce2516927771881427f56c1d\">Gastrointestinal</span> Stromal Tumors (GIST)</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Vandetanib, Cabozantinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Medullary <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> of the Thyroid</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Midostaurin, Gilteritinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-color:#000000; border-style:solid\">\n\t\t\t<p>Acute <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">Myeloid</span> <span class=\"customMeta\" data-dictid=\"4521dbf4b91692777191a73002bf98\">Leukemia</span> (AML) with FLT-3 mutation</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>FGFR Inhibitors and uses:</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug Name</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Clinical Use</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Erdafitinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Urothelial Carcinoma</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Pemigatinib, Infigratinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Cholangiocarcinoma</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/0C8jhujzXaGTU5Jv4mnG1749201687.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/W6FZnYbZmxb7EZQ9aNQr1749201642.mp3"
    },
    {
      "text": "A 58-year-old male patient diagnosed with malignant melanoma has not responded to initial therapies. His oncologist is considering targeted therapy options. Which of the following inhibitors can be used in malignant melanoma?",
      "choices": [
        {
          "id": 0,
          "text": "Sirolimus"
        },
        {
          "id": 1,
          "text": "Binimetinib"
        },
        {
          "id": 2,
          "text": "Idelalisib"
        },
        {
          "id": 3,
          "text": "Adagrasib"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) Binimetinib</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>Binimetinib is a MEK inhibitor, used specifically in <span class=\"customMeta\" data-dictid=\"f8aaf091221692777191f73e810e94\">malignant</span> melanoma. MEK Inhibitors belong to the class of Protein <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">Kinase</span> <span class=\"customMeta\" data-dictid=\"f9016f36fd1692777198b0fd5e9c6d\">Signaling</span> Inhibitors.</p>\n\n<p><strong>Protein <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">Kinase</span> <span class=\"customMeta\" data-dictid=\"f9016f36fd1692777198b0fd5e9c6d\">Signaling</span> Inhibitors:</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:625px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>Inhibitor Type</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>Drugs</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>Uses</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>RAS Inhibitors</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>Sotorasib, <strong>Adagrasib</strong> <strong>(Option D Ruled out)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>NSCLC with KRAS mutation</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>B-RAF Inhibitors</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>Vemurafenib, Dabrafenib, Encorafenib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>Malignant <span class=\"customMeta\" data-dictid=\"e42297345d16927771922d2d0dc020\">Melanoma</span> with B-RAF mutation</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>MEK Inhibitors</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>Trametinib, Cobimetinib, <strong>Binimetinib (Option B)</strong>, Selumetinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>Malignant Melanoma</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>PI3K Inhibitors</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>Idelalisib</strong> <strong>(Option C Ruled out)</strong>, Copanlisib, Duvelisib, Umbralisib, Alpelisib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>B Cell <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">Lymphoma</span> (CLL, SLL, FL)</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>mTOR Inhibitors</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p><strong>Sirolimus (Option A Ruled out)</strong>, Temsirolimus, Everolimus</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n\t\t\t<p>RCC (Renal Cell Carcinoma), Breast Cancer, <span class=\"customMeta\" data-dictid=\"cde2dcfb251692777195bb7a41d550\">PNET</span> (Pancreatic <span class=\"customMeta\" data-dictid=\"7eca2476201692777193e0a0959bd7\">Neuroendocrine</span> Tumors)</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><br />\n </p>\n\n<p> </p>\n\n<p><br />\n </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/ITZAdGwJCILEaPyNOkak1749203740.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/4pcZA1mhAEndBIEO8aTj1749203688.mp3"
    },
    {
      "text": "A 52-year-old female presents with a diagnosis of invasive ductal carcinoma of the breast. The tumour measures 3 cm in diameter and has been staged as T2N1M0. Immunohistochemical testing reveals that the cancer cells overexpress the HER2 protein and are ER-negative. The patient has no significant comorbidities and has been scheduled for surgery. Which of the following drugs is most suitable for this patient as part of her adjuvant chemotherapy regimen",
      "choices": [
        {
          "id": 0,
          "text": "Tamoxifen"
        },
        {
          "id": 1,
          "text": "Cetuximab"
        },
        {
          "id": 2,
          "text": "Trastuzumab"
        },
        {
          "id": 3,
          "text": "Bevacizumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Trastuzumab</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<ul>\n\t<li><strong>Trastuzumab (Option C) </strong>is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> <span class=\"customMeta\" data-dictid=\"e4865847fa169277720044d7b530b0\">targeting</span> the HER2 protein, which is overexpressed in HER2-positive breast cancers. This patient has HER2 +ve, ER -ve stage II breast cancer.</li>\n\t<li>It binds to the <span class=\"customMeta\" data-dictid=\"ba366417791692777187229d34e597\">extracellular</span> domain IV of HER2, reduces HER2 signaling, and can induce antibody-dependent, immune cell-mediated cytotoxicity, inhibiting cancer cell proliferation.</li>\n\t<li>It is specifically used to treat HER2-positive breast cancer, both in early-stage and metastatic settings.</li>\n</ul>\n\n<p><strong>Tamoxifen (Option A):</strong></p>\n\n<ul>\n\t<li>A selective <span class=\"customMeta\" data-dictid=\"a58dd68b011692777187eb72633aac\">estrogen</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> <span class=\"customMeta\" data-dictid=\"a4dd3586e816927771927d01e3fe29\">modulator</span> (SERM), binds to <span class=\"customMeta\" data-dictid=\"a58dd68b011692777187eb72633aac\">estrogen</span> receptors on breast cancer cells, thereby <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> the effects of estrogen, which can promote the growth of breast cancer cells.</li>\n\t<li>It is primarily used for <span class=\"customMeta\" data-dictid=\"a58dd68b011692777187eb72633aac\">estrogen</span> receptor-positive (ER+) breast cancer.</li>\n</ul>\n\n<p><strong>Cetuximab (Option B)</strong>:</p>\n\n<ul>\n\t<li>It is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that targets the <span class=\"customMeta\" data-dictid=\"616d85c57416927771875ef23f6751\">epidermal</span> growth factor <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> (EGFR) and thus prevents cell proliferation.</li>\n\t<li>It treats certain types of <span class=\"customMeta\" data-dictid=\"f04bf2125316927771847bfe139191\">colorectal</span> and head and neck cancers that overexpress EGFR rather than HER2.</li>\n</ul>\n\n<p><strong>Bevacizumab (Option D):</strong></p>\n\n<ul>\n\t<li>It is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that targets <span class=\"customMeta\" data-dictid=\"526ede3fee169277720184378acc5e\">vascular</span> endothelial growth factor (VEGF), inhibiting angiogenesis.</li>\n\t<li>It is used for metastatic <span class=\"customMeta\" data-dictid=\"f04bf2125316927771847bfe139191\">colorectal</span> cancer, non-small cell lung cancer, <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">renal</span> cell carcinoma, and glioblastoma. It is not usually associated with the treatment of HER2 +ve breast cancer.</li>\n</ul>\n\n<p><strong>Important MABs in tumours:</strong></p>\n\n<p><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"1824\" src=\"https://image.prepladder.com/content/KI5ffGfpZT4iiU50IllV1736435764.png\" width=\"1999\" /></p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/KI5ffGfpZT4iiU50IllV1736435764.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/aPMiFcXO9Qfi2vqZVno11749203907.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/7m5d8vT7x9OXS59zgLHO1749203834.mp3"
    },
    {
      "text": "A 60-year-old male with a significant smoking history presents with a persistent cough, dyspnea, weight loss, and fatigue. A Chest CT reveals a suspicious mass in the right upper lobe. A biopsy of the mass shows adenocarcinoma. Further molecular testing reveals high PD-L1 expression (>50%) and no actionable mutations in EGFR, ALK, or ROS1. Which of the following drugs would you choose as the first line of treatment in this case?",
      "choices": [
        {
          "id": 0,
          "text": "Erlotinib"
        },
        {
          "id": 1,
          "text": "Bevacizumab"
        },
        {
          "id": 2,
          "text": "Pembrolizumab"
        },
        {
          "id": 3,
          "text": "Ipilimumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Pembrolizumab</strong></p>\n\n<p> </p>\n\n<p><strong>Explanation: </strong></p>\n\n<ul>\n\t<li><strong>Pembrolizumab</strong> is an immune <span class=\"customMeta\" data-dictid=\"cd249aae061692777184c11176df48\">checkpoint</span> <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> that targets the PD-1 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on T-cells.</li>\n\t<li>The patient's symptoms, CT findings, molecular testing, and <span class=\"customMeta\" data-dictid=\"754ab07a2e1692777183ed178c883d\">biopsy</span> tests of <span class=\"customMeta\" data-dictid=\"362992dbb11692777180f9017fc04d\">adenocarcinoma</span> (the most common subtype of NSCLC) results are typical presentations for a patient with non-small cell lung <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">carcinoma</span> (NSCLC).</li>\n\t<li>Here, the patient has<strong> </strong>high PD-L1 expression (>50%).</li>\n\t<li>Pembrolizumab is particularly effective in NSCLC patients with high PD-L1 expression (≥50%) and is approved as a first-line treatment for these patients when there are no actionable mutations in EGFR, ALK, or ROS1.</li>\n</ul>\n\n<p><strong>MOA of Immune <span class=\"customMeta\" data-dictid=\"cd249aae061692777184c11176df48\">Checkpoint</span> Inhibitors:</strong></p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"1516\" src=\"https://image.prepladder.com/content/lWKK6hhPg6yCL2JANa4U1736435838.png\" width=\"1999\" /></p>\n\n<p> </p>\n\n<p><strong>Erlotinib (Option A): </strong></p>\n\n<ul>\n\t<li>It is a tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> (TKI) that targets the EGFR. These mutations are more common in non-smokers.</li>\n</ul>\n\n<p><strong>Bevacizumab (Option B): </strong></p>\n\n<ul>\n\t<li>It is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that inhibits VEGF, thereby inhibiting angiogenesis.</li>\n\t<li>It is used in combination with <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> for certain types of cancer, including NSCLC.</li>\n</ul>\n\n<p><strong>Ipilimumab (Option D)</strong>:</p>\n\n<ul>\n\t<li>It is a CTLA-4 inhibitor.</li>\n\t<li>By <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> CTLA-4, ipilimumab enhances T-cell <span class=\"customMeta\" data-dictid=\"ba6b77f29316927771807350f86ce2\">activation</span> and proliferation, promoting an <span class=\"customMeta\" data-dictid=\"dc6add5cf91692777189b30a6bae38\">immune response</span> against cancer cells.</li>\n</ul>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"1335\" src=\"https://image.prepladder.com/content/T9qsYnDojI7vWUDTbesP1736435889.png\" width=\"1999\" /></p>\n\n<p> </p>\n\n<p><strong>Immune <span class=\"customMeta\" data-dictid=\"cd249aae061692777184c11176df48\">Checkpoint</span> Inhibitors and their uses:</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:NaN\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Blocks CTLA4 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> </strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Blocks PD-L-1 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> </strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align: center;\"><strong>Blocks PD-1 receptor</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Ipilimumab</li>\n\t\t\t\t<li>Tremelimumab</li>\n\t\t\t</ul>\n\t\t\t<br />\n\t\t\t </td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Atezolizumab</li>\n\t\t\t\t<li>Avelumab</li>\n\t\t\t\t<li>Durvalumab</li>\n\t\t\t</ul>\n\t\t\t<br />\n\t\t\t </td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Nivolumab</li>\n\t\t\t\t<li>Cepilimumab</li>\n\t\t\t\t<li>Pembrolizumab</li>\n\t\t\t</ul>\n\n\t\t\t<p> </p>\n\n\t\t\t<p> </p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/lWKK6hhPg6yCL2JANa4U1736435838.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/QEday2gHpta3zqV73ZZB1749204044.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/xPL3jaOXgJxzmVz35tEL1749203980.mp3"
    },
    {
      "text": "A 45-year-old man presents to the dermatology clinic with chronic, thick, silvery-white, scaly plaques on his elbows, knees, and lower back. He reports that the plaques have been present for several years and have gradually worsened. He has tried various OTC creams with minimal relief. The plaques are extensive on examination, and the patient rates his itching and discomfort as moderate to severe. Which of the following drugs is NOT relevant for this patient’s treatment?",
      "choices": [
        {
          "id": 0,
          "text": "Ixekizumab"
        },
        {
          "id": 1,
          "text": "Secukinumab"
        },
        {
          "id": 2,
          "text": "Etanercept"
        },
        {
          "id": 3,
          "text": "Mogamulizumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) Mogamulizumab</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<p>This patient’s clinical findings are characteristic of <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">Plaque</span> psoriasis. Mogamulizumab is unsuitable for treating <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">plaque</span> psoriasis.</p>\n\n<p><strong>Mogamulizumab</strong>:</p>\n\n<ul>\n\t<li>It is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that targets CCR4, which is expressed on certain T-cells, including <span class=\"customMeta\" data-dictid=\"f8aaf091221692777191f73e810e94\">malignant</span> T-cells in <span class=\"customMeta\" data-dictid=\"94f1c8df1f1692777185bd6a7c3fff\">cutaneous</span> T-cell <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">lymphoma</span> (CTCL), where it is used as a primary agent for treatment.</li>\n\t<li>It is mainly used as a treatment for relapsed <span class=\"customMeta\" data-dictid=\"a1e130c1691692777192c7da13c523\">mycosis</span> fungoides & Sezary syndrome.</li>\n\t<li>Mogamulizumab is unsuitable for treating <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">plaque</span> <span class=\"customMeta\" data-dictid=\"8b9f55244b1692777196b5ddb9a6bf\">psoriasis</span> because it does not target the mechanisms underlying <span class=\"customMeta\" data-dictid=\"8b9f55244b1692777196b5ddb9a6bf\">psoriasis</span> inflammation, such as TNF-alpha or IL-17A.</li>\n</ul>\n\n<p><strong>Ixekizumab (Option A) & Secukinumab (Option B) </strong>are <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> antibodies that specifically target interleukin-17A (IL-17A), a pro-inflammatory <span class=\"customMeta\" data-dictid=\"0ac01cc0c31692777185cae5f28175\">cytokine</span> involved in the <span class=\"customMeta\" data-dictid=\"715b4caf0316927771943797627d8d\">pathogenesis</span> of psoriasis. They are indicated for treating moderate to severe <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">plaque</span> <span class=\"customMeta\" data-dictid=\"8b9f55244b1692777196b5ddb9a6bf\">psoriasis</span> in adults.</p>\n\n<p><strong>Etanercept (Option C)</strong> is a <span class=\"customMeta\" data-dictid=\"845fedd06d16927771989597afa034\">soluble</span> TNF-alpha <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> protein that binds to and neutralizes TNF-alpha, a key <span class=\"customMeta\" data-dictid=\"0ac01cc0c31692777185cae5f28175\">cytokine</span> involved in the <span class=\"customMeta\" data-dictid=\"9d21dd5d3116927771907405b181bc\">inflammatory</span> process in psoriasis. It is indicated for treating moderate to severe <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">plaque</span> psoriasis, psoriatic arthritis, and other <span class=\"customMeta\" data-dictid=\"96ab11a06a16927771823151c8e471\">autoimmune</span> conditions.</p>\n\n<p><strong>MABs used in <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">Plaque</span> Psoriasis</strong></p>\n\n<p><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"1099\" src=\"https://image.prepladder.com/content/UxLbMXCiokQFduwWthCp1736435945.png\" width=\"1813\" /></p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/UxLbMXCiokQFduwWthCp1736435945.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/K5dZEV9Xo8Y1CkIJjedH1749204195.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/ClD8mEt4D3L1Da7Lw2Eg1749204129.mp3"
    },
    {
      "text": "A 65-year-old male with hypertension and CKD presents with gross hematuria and flank pain. Imaging studies reveal a 7 cm mass in the left kidney concerning renal cell carcinoma. He undergoes a radical nephrectomy with pathological confirmation of clear cell RCC, pT3aN0M0 (stage III). Due to his advanced stage, you are considering adjuvant therapy with Aldesleukin. Which of the following is a potential mechanism of action of aldesleukin in treating RCC?",
      "choices": [
        {
          "id": 0,
          "text": "Induction of angiogenesis"
        },
        {
          "id": 1,
          "text": "Activation of T cells"
        },
        {
          "id": 2,
          "text": "Inhibition of vascular endothelial growth factor (VEGF)"
        },
        {
          "id": 3,
          "text": "Direct cytotoxicity against tumor cells"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) <span class=\"customMeta\" data-dictid=\"ba6b77f29316927771807350f86ce2\">Activation</span> of T cells</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<ul>\n\t<li>Aldesleukin (IL-2) stimulates the <span class=\"customMeta\" data-dictid=\"8eedb6cec61692777196a6a3b93d3f\">proliferation</span> of activated T cells and the <span class=\"customMeta\" data-dictid=\"9b0ae3750916927771986c15d4ff4d\">secretion</span> of cytokines from NK cells and monocytes. IL-2 <span class=\"customMeta\" data-dictid=\"7f3792072b1692777199fd8e2c4f59\">stimulation</span> increases cytotoxic killing by T cells and NK cells.</li>\n\t<li>In the context of <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">renal</span> cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">carcinoma</span> (RCC), it enhances immune responses against tumour cells, leading to their destruction.</li>\n</ul>\n\n<p><strong>Other <span class=\"customMeta\" data-dictid=\"13a516845f1692777190749910c8fc\">Interleukin</span> used in cancer:</strong></p>\n\n<p>Denileukin Diftitox is an IL2 <span class=\"customMeta\" data-dictid=\"8d0fca798b1692777191b6cd41880f\">linked</span> with <span class=\"customMeta\" data-dictid=\"233cc736b01692777186a2a5ac98f1\">diphtheria</span> <span class=\"customMeta\" data-dictid=\"41329dc9381692777200a9b6d57cf4\">toxin</span> and is used in <span class=\"customMeta\" data-dictid=\"94f1c8df1f1692777185bd6a7c3fff\">cutaneous</span> T-cell lymphomas.</p>\n\n<p><strong>Induction of <span class=\"customMeta\" data-dictid=\"2c25c78eca1692777181c8c8fdae31\">angiogenesis</span> (Option A)</strong>: <span class=\"customMeta\" data-dictid=\"90979a4bb91692777181974b0084a0\">Aldesleukin</span> does not induce angiogenesis; rather, it enhances the <span class=\"customMeta\" data-dictid=\"dc6add5cf91692777189b30a6bae38\">immune response</span> against tumours.</p>\n\n<p><strong>Inhibition of <span class=\"customMeta\" data-dictid=\"526ede3fee169277720184378acc5e\">vascular</span> endothelial growth factor (VEGF) (Option C)</strong>: <span class=\"customMeta\" data-dictid=\"90979a4bb91692777181974b0084a0\">Aldesleukin</span> does not directly <span class=\"customMeta\" data-dictid=\"6b3de87b7c16927771901326efbcd2\">inhibit</span> VEGF.</p>\n\n<p><strong>Direct <span class=\"customMeta\" data-dictid=\"569eae3b3516927771850ba9123b99\">cytotoxicity</span> against tumour cells (Option D)</strong>: <span class=\"customMeta\" data-dictid=\"90979a4bb91692777181974b0084a0\">Aldesleukin</span> primarily works through immune-mediated mechanisms rather than direct cytotoxic effects.</p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/uzMvX5AebGCwqNMXeeuV1749204331.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/Hci8awYtOQOrExMTYUKv1749204273.mp3"
    },
    {
      "text": "A 65-year-old male with refractory multiple myeloma has undergone multiple lines of treatment including proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation. Despite these treatments, his disease has progressed. His oncologist decided to start him on a novel therapy that targets B-cell maturation antigen (BCMA) and delivers a cytotoxic agent to myeloma cells.\nWhich drug is the patient likely being prescribed?",
      "choices": [
        {
          "id": 0,
          "text": "Daratumumab"
        },
        {
          "id": 1,
          "text": "Elotuzumab"
        },
        {
          "id": 2,
          "text": "Belantamab Vedotin"
        },
        {
          "id": 3,
          "text": "Ixekizumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct Answer: C) Belantamab Vedotin</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<p>Belantamab Vedotin is an armed <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> or an antibody-toxin <span class=\"customMeta\" data-dictid=\"2421c657771692777185af1b7b59c3\">conjugate</span> approved for the treatment of <span class=\"customMeta\" data-dictid=\"3790c638ab16927771970a0a41d3ab\">refractory</span> multiple myeloma.</p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Target</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Approved for</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Gemtuzumab Ozogamicin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· CD33 + Calicheamicin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Relapsed AML</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Brentuximab Vedontin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· CD30 + Vedontin</p>\n\n\t\t\t<p>(microtubule cleaver)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· Hodgkin's <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">lymphoma</span> (refractory)</p>\n\n\t\t\t<p>· Large B-cell lymphoma</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Belantamab Vedontin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· BCMA+ Vedontin</p>\n\n\t\t\t<p>(microtubule cleaver)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· <span class=\"customMeta\" data-dictid=\"3790c638ab16927771970a0a41d3ab\">Refractory</span> multiple myeloma</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Polatuzumab Vedontin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· CD19 + Vedontin</p>\n\n\t\t\t<p>(microtubule cleaver)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· Relapsed AML</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Moxetumomab Pasudotox</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· CD22 + <span class=\"customMeta\" data-dictid=\"8d0fca798b1692777191b6cd41880f\">Linked</span> to <span class=\"customMeta\" data-dictid=\"dea08f9dd81692777196a5f62e6862\">pseudomonas</span> <span class=\"customMeta\" data-dictid=\"41329dc9381692777200a9b6d57cf4\">toxin</span> A</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>· <span class=\"customMeta\" data-dictid=\"a4789768d21692777188e77f1969cd\">Hairy</span> cell leukemia</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Daratumumab (Option A)</strong>: Acts by <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> CD38 and is used in the treatment of multiple myeloma.</p>\n\n<p><strong>Elotuzumab (Option B)</strong>: Acts by <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> CD319 and is used in the treatment of multiple myeloma.</p>\n\n<p><strong>Ixekizumab (Option D):</strong> Acts by <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> IL-17 and is used in the treatment of <span class=\"customMeta\" data-dictid=\"af71c1668e169277719542cf8f1364\">plaque</span> psoriasis.</p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/l5tcWgfnghwVYquCrAPv1749204551.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/KA3bjShJqgHVHL7LPytD1749204476.mp3"
    },
    {
      "text": "A 58-year-old female with metastatic melanoma has experienced disease progression after treatment with a BRAF inhibitor and an immune checkpoint inhibitor targeting CTLA-4. Her oncologist now recommends a monoclonal antibody Pembrolizumab, that targets the PD-1 receptor to help reinvigorate T-cell activity against the tumor. Pembrolizumab can be used in the treatment of all of the following, except?",
      "choices": [
        {
          "id": 0,
          "text": "Non-small cell lung cancer"
        },
        {
          "id": 1,
          "text": "Breast cancer"
        },
        {
          "id": 2,
          "text": "Renal Cell carcinoma"
        },
        {
          "id": 3,
          "text": "Multiple myeloma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct Answer: D) Multiple myeloma</strong></p>\n\n<p><strong>Explanation: </strong></p>\n\n<p><br />\nPembrolizumab is an immune <span class=\"customMeta\" data-dictid=\"cd249aae061692777184c11176df48\">checkpoint</span> <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> that targets the PD-1 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on T-cells. It has various clinical uses which can be summarized using the following mnemonic.</p>\n\n<p><strong>Pembrolizumab uses: (Mnemonic)</strong></p>\n\n<ul>\n\t<li>P: <strong>Pulmonary cancer/ NSCLC</strong> (Tested in <span class=\"customMeta\" data-dictid=\"ebe5056f631692777190f77f4785f4\">Keynote</span> trial) <strong>(Option A)</strong></li>\n\t<li>E: Endometrial cancer</li>\n\t<li>M: Melanoma</li>\n\t<li>B: <strong>Breast cancer (Option B)</strong></li>\n\t<li>R: <strong>Renal cell carcinoma (Option C)</strong></li>\n\t<li>O: Oesophagus, stomach cancer</li>\n\t<li>L: Lynch Syndrome/Mismatch DNA</li>\n\t<li>I: Intestinal cancer/Colorectal</li>\n\t<li>Z: Neck & head cancer</li>\n\t<li>U: Urothelial + <span class=\"customMeta\" data-dictid=\"0e919a208b16927771885d9c1f6662\">genital</span> cancer</li>\n\t<li>M: Merkel cell cancer, <span class=\"customMeta\" data-dictid=\"1014e4cf5e169277719246e0ca91df\">mediastinal</span> cancer</li>\n\t<li>A: <span class=\"customMeta\" data-dictid=\"458e050fdc16927771809854c9fd53\">Abnormal</span> <span class=\"customMeta\" data-dictid=\"20b150babc1692777192cc2f5fe1e3\">microsatellite</span> <span class=\"customMeta\" data-dictid=\"acb259200b16927771908888d1377c\">instability</span> cancer</li>\n\t<li>B: B cell cancer (large)</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/pbUibPRcIOth5p8Om4ZG1749203592.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/gvI8aRrhjDPEmfcxMFTp1749203538.mp3"
    },
    {
      "text": "A 48-year-old woman with newly diagnosed HER2-positive invasive ductal carcinoma is started on a neoadjuvant therapy that includes a monoclonal antibody. This antibody specifically binds to the extracellular domain of the HER2 receptor, blocking the activation of downstream signaling pathways involved in cell growth and survival. Additionally, it enhances antibody-dependent cellular cytotoxicity (ADCC), leading to improved immune-mediated destruction of tumor cells. Despite the initial efficacy of the treatment, her oncologist monitors her closely for potential cardiotoxicity, a known side effect of this therapy. Which monoclonal antibody is the patient most likely receiving?",
      "choices": [
        {
          "id": 0,
          "text": "Pertuzumab"
        },
        {
          "id": 1,
          "text": "Trastuzumab"
        },
        {
          "id": 2,
          "text": "Cetuximab"
        },
        {
          "id": 3,
          "text": "Bevacizumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct Answer: B) Trastuzumab</strong></p>\n\n<p><br />\n<strong>Explanation: </strong></p>\n\n<p>Trastuzumab is a humanized IgG1 <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that binds to the <span class=\"customMeta\" data-dictid=\"ba366417791692777187229d34e597\">extracellular</span> domain IV of HER2, reduces HER2 signaling, and can induce antibody-dependent, immune cell–mediated cytotoxicity.</p>\n\n<p><br />\n<strong>Mechanism of action: </strong>Blocks HER2/Neu receptor</p>\n\n<p><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"1032\" src=\"https://image.prepladder.com/content/VvBJg36GLVy5qZ4ihGbw1736436022.png\" width=\"1969\" /></p>\n\n<p><strong>Therapeutic Uses:</strong></p>\n\n<ul>\n\t<li>Trastuzumab is approved for HER2-overexpressing breast and <span class=\"customMeta\" data-dictid=\"12347b15191692777188bc86d226e1\">gastric</span> cancer.</li>\n\t<li>It is used in combination with cytotoxic <span class=\"customMeta\" data-dictid=\"721ab08250169277718402cade7633\">chemotherapeutics</span> such as taxanes as initial treatment or as a single agent following <span class=\"customMeta\" data-dictid=\"b4b361c37616927771979541177070\">relapse</span> of disease after cytotoxic chemotherapy.</li>\n</ul>\n\n<p><strong>Side effects of Trastuzumab:</strong></p>\n\n<ul>\n\t<li>Cardiotoxic</li>\n\t<li>Should be avoided with <span class=\"customMeta\" data-dictid=\"845ffca50f1692777186d5ed72e81a\">Doxorubicin</span> (>30%)</li>\n</ul>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/VvBJg36GLVy5qZ4ihGbw1736436022.png"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/6JHS0H6VN1m5ri8ziL7c1749203461.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/co4U620TW6YEeZYF2aVk1749203420.mp3"
    }
  ]
}